SAN FRANCISCO (KRON) – A man hospitalized at UCSF Health is being treated for rare blood clots he developed nearly two weeks after receiving the Johnson & Johnson vaccine.

According to UCSF, the male patient is believed to be the first man in the U.S. with VITT syndrome – vaccine-induced thrombotic thrombocytopenia – in the U.S. following the U.S. emergency authorization of the J&J vaccine on Feb. 27.

Officials described the patient as a Bay Area resident in his early 30s, and said he was making a “good recovery” and is “expected to be discharged within a few days.”

“He was admitted April 21 with escalating pain in the lower back and leg, and received the recommended therapy for VITT, which includes intravenous immune globulin, the anticoagulant argatroban, and prednisone,” the hospital said in a statement.

The news comes after the state gave the OK to resume the use of the Johnson & Johnson vaccine after federal scientific advisers decided its benefits outweigh a rare risk of blood clots.

The federal government uncovered 15 vaccine recipients who developed a highly unusual kind of blood clot out of nearly 8 million people given the J&J shot. All were women, most under age 50. Three died, and seven remain hospitalized.

But ultimately, federal health officials decided that J&J’s one-and-done vaccine is critical to fight the pandemic — and that the small clot risk could be handled with warnings to help younger women decide if they should use that shot or an alternative.

The Associated Press contributed to this report.